Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection
Authors
Keywords
Vancomycin, Clostridium Difficile Infection, Rifaximin, Clinical Cure Rate, Fidaxomicin
Journal
DRUGS
Volume 73, Issue 15, Pages 1733-1747
Publisher
Springer Nature
Online
2013-10-17
DOI
10.1007/s40265-013-0134-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials
- (2013) Kathleen M. Mullane et al. AMERICAN JOURNAL OF NEPHROLOGY
- Comparative Effectiveness ofClostridium difficileTreatments
- (2013) Dimitri M. Drekonja et al. ANNALS OF INTERNAL MEDICINE
- Advances in the treatment ofClostridium difficilewith fidaxomicin: a narrow spectrum antibiotic
- (2013) Pamela Sears et al. Annals of the New York Academy of Sciences
- Is Fidaxomicin Worth the Cost? An Economic Analysis
- (2013) Sarah M. Bartsch et al. CLINICAL INFECTIOUS DISEASES
- European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection
- (2013) S.B. Debast et al. CLINICAL MICROBIOLOGY AND INFECTION
- Resolution of Clostridium difficile–Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin
- (2013) Oliver A. Cornely et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Age on Treatment Outcomes inClostridium difficileInfection
- (2013) Thomas J. Louie et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States
- (2013) Paul M. Stranges et al. VALUE IN HEALTH
- ComparativeIn VitroActivities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria
- (2012) Diane M. Citron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
- (2012) Charlotte A. Allen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterizations of Clinical Isolates of Clostridium difficile by Toxin Genotypes and by Susceptibility to 12 Antimicrobial Agents, Including Fidaxomicin (OPT-80) and Rifaximin: a Multicenter Study in Taiwan
- (2012) Chun-Hsing Liao et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- (2012) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
- (2012) M. M. Nerandzic et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Inhibits Spore Production in Clostridium difficile
- (2012) Farah Babakhani et al. CLINICAL INFECTIOUS DISEASES
- Antimicrobial Activities of Fidaxomicin
- (2012) Ellie J. C. Goldstein et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
- (2012) Irina Artsimovitch et al. CLINICAL INFECTIOUS DISEASES
- Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
- (2012) I. Figueroa et al. CLINICAL INFECTIOUS DISEASES
- Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain
- (2012) Laurica A. Petrella et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
- (2012) Derrick W. Crook et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
- (2012) P. Sears et al. CLINICAL INFECTIOUS DISEASES
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
- (2012) O. A. Cornely et al. CLINICAL INFECTIOUS DISEASES
- Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
- (2012) O.A. Cornely CLINICAL MICROBIOLOGY AND INFECTION
- Fidaxomicin: a new option for the treatment of Clostridium difficile infection
- (2012) A. P. Johnson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fidaxomicin inhibits toxin production in Clostridium difficile
- (2012) F. Babakhani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Clostridium difficile Infection: New Insights Into Management
- (2012) Sahil Khanna et al. MAYO CLINIC PROCEEDINGS
- PIN35 Decision Analysis Model Evaluating the Cost-Effectiveness of Fidaxomicin and Vancomycin in the Treatment of Clostridium Difficile Infection (CDI) from a Hospital Perspective
- (2012) M.S. Alowayesh et al. VALUE IN HEALTH
- PGI21 a Comparison of the Cost-Effectiveness of Fidaxomicin, Metronidazole, and Vancomycin, in the Treatment of Clostridium Difficile-Associated Disease
- (2012) N. Madkour et al. VALUE IN HEALTH
- Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures
- (2012) Jane A. Cecil Current Infectious Disease Reports
- Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
- (2011) Farah Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection
- (2011) Ellie J. C. Goldstein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
- (2011) Kathleen M. Mullane et al. CLINICAL INFECTIOUS DISEASES
- Recurrent Clostridium difficile Infection
- (2011) Claire M.F. van Nispen tot Pannerden et al. DRUGS
- Fidaxomicin
- (2011) Sean T. Duggan DRUGS
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
- (2011) F. Babakhani et al. JOURNAL OF MEDICAL MICROBIOLOGY
- The Search for Effective Treatment ofClostridium difficileInfection
- (2011) Herbert L. DuPont NEW ENGLAND JOURNAL OF MEDICINE
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Inoculum, pH, and Cations on the In Vitro Activity of Fidaxomicin (OPT-80, PAR-101) against Clostridium difficile
- (2010) F. Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- (2010) Stuart H. Cohen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
- (2010) G. W. Tannock et al. MICROBIOLOGY-SGM
- In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile
- (2008) J. A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses
- (2008) Y. K. Shue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection
- (2008) T. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection
- (2008) T. J. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More